Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(31 sites)

United States

Banner MD Anderson Cancer Center, Gilbert, Arizona

City of Hope, Duarte, California

City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California

Cancer and Blood Specialty Clinic, Los Alamitos, California

University of California San Francisco, San Francisco, California

Cancer Specialists of North Florida, Jacksonville, Florida

Emory University, Atlanta, Georgia

Northside Hospital Cancer Institute, Atlanta, Georgia

Cancer Care Specialists of Central Illinois, O'Fallon, Illinois

University of Iowa, Iowa City, Iowa

Mission Cancer Blood, Waukee, Iowa

Massachusetts General Hospital, Boston, Massachusetts

Rutgers Cancer Institute, New Brunswick, New Jersey

Memorial Sloan Kettering Cancer Center, New York, New York

Cleveland Clinic Foundtation, Cleveland, Ohio

University of Pennsylvania, Philadelphia, Pennsylvania

SCRI Oncology Partners, Nashville, Tennessee

Tennessee Oncology, PLLC, Nashville, Tennessee

Texas Oncology, Austin, Texas

MD Anderson Cancer Center, Houston, Texas

Oncology Consultants Texas, Houston, Texas

Texas Oncology - Northeast, Tyler, Texas

NorthWest Medical Specialties, PLLC, Tacoma, Washington

Israel

Ha'Emek Medical Center, Afula

Samson Assuta Ashdod University Hospital, Ashdod

Hillel Yaffe Medical Center, Hadera

Hadassah Medical Center, Jerusalem

Rabin Medical Center, Petah Tikva

Tel Aviv Sourasky Medical Center, Tel Aviv

Japan

National Hospital Organization Shibukawa Medical Center, Gunma

National Hospital Organization Okayama Medical Center, Okayama